PE-22-28 – 10mg Peptide

PE-22-28 (10mg) — Research Compound

PE-22-28 is a synthetic peptide derived from spadin, studied for its role as a selective blocker of the TREK-1 potassium channel. TREK-1 is primarily expressed in the brain, particularly in areas associated with mood and cognitive function, such as the hippocampus. Researchers investigate PE-22-28 for its potential to act as a rapid-onset antidepressant by modulating neuronal excitability and stimulating neurogenesis without the lag time associated with traditional serotonergic therapies.

Findings from early-stage clinical trials have reported:

• Rapid improvements in mood-related behavioral markers observed within four days in experimental models.
• Significant increases in the levels of Brain-Derived Neurotrophic Factor (BDNF) reported in hippocampal research.
• Enhanced rates of neurogenesis (new neuron growth) noted across multiple study cohorts.
• No observed impact on cardiovascular markers or traditional potassium channel side effects in research studies.

Researchers study PE-22-28 to investigate the role of TREK-1 signaling in the regulation of mental health and neuroplasticity. Its ability to trigger neurogenic pathways rapidly makes it a specialized tool for understanding the biological response to acute stress. This compound is a primary focus for research into the next generation of fast-acting neurotrophic agents and the mechanisms of neuronal resilience.

Available Formats:
This compound is available as a vial of lyophilised powder, or can be ordered in a disposable pen, a reusable pen, or a cartridge for an existing reusable pen system.

Used solely for in vitro experiments and cannot be:

• Used in clinical trials involving humans
• Administered to humans as part of an experiment or investigation
• Supplied to another party for human investigational use